Ribociclib Improves Overall Survival in HR+/HER2– Metastatic Breast Cancer Across Common Genomic and Clinical Subtypes

In updated biomarker and clinical subgroup analyses from the phase III MONALEESA trials, ribociclib demonstrated consistent improvements in overall survival when added to endocrine therapy in patients with HR-positive/HER2-negative advanced breast cancer.

Detalles Bibliográficos
Autor principal: Jacobson, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Conference Perspectives: Highlights from SABCS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963148/
https://www.ncbi.nlm.nih.gov/pubmed/35348783
http://dx.doi.org/10.1093/oncolo/oyac010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963148/
https://www.ncbi.nlm.nih.gov/pubmed/35348783
http://dx.doi.org/10.1093/oncolo/oyac010

Ejemplares similares